यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

tigenix n.v. - cellules de cartilage autologues viables caractérisées expansées ex vivo exprimant des protéines de marquage spécifiques - maladies du cartilage - autres médicaments pour les troubles du système musculo-squelettique - réparation des anomalies du cartilage symptomatique unique du condyle fémoral du genou (international cartilage repair society [icrs] grade iii ou iv) chez l'adulte. concomitante asymptomatiques lésions du cartilage (rvs de grade i ou ii) pourraient être présents. démonstration de l'efficacité est basée sur un essai contrôlé randomisé évaluant l'efficacité de chondrocelect chez les patients avec des lésions entre 1 et 5 cm2.

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pierre fabre benelux sa-nv - isotrétinoïne 40 mg - capsule molle - 40 mg - isotrétinoïne 40 mg - isotretinoin

यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents contre la dermatite, à l'exclusion des corticostéroïdes - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

vericel denmark aps - chondrocytes cultivés autologues - fractures, cartilage - autres médicaments pour les troubles du système musculo-squelettique - réparation des défauts cartilagineux symptomatiques du genou.

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pierre fabre benelux sa-nv - isotrétinoïne 5 mg - capsule molle - 5 mg - isotrétinoïne 5 mg - isotretinoin

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pierre fabre benelux sa-nv - isotrétinoïne 10 mg - capsule molle - 10 mg - isotrétinoïne 10 mg - isotretinoin

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pierre fabre benelux sa-nv - isotrétinoïne 20 mg - capsule molle - 20 mg - isotrétinoïne 20 mg - isotretinoin

यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - le trioxyde d'arsenic - leucémie, promyélocytaire, aiguë - agents antinéoplasiques - arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with:newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (apl) (white blood cell count, ≤ 10 x 10³/μl) in combination with all-trans-retinoic acid (atra)relapsed/refractory apl (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (pml/rarα) gene. le taux de réponse des autres sous-types de leucémie myéloïde aiguë pour le trioxyde d'arsenic n'a pas été examiné.

यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

idorsia pharmaceuticals deutschland gmbh - daridorexant hydrochloride - initiation au sommeil et troubles de la maintenance - psycholeptiques - quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.

यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - mélatonine - initiation au sommeil et troubles de la maintenance - psycholeptiques - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.